3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Adenocarcinoma of Lung
1
Interventions
Carboplatin
6
Radiotherapy
5
Radiation
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
Specimen Handling
3
Pemetrexed
3
Biopsy
3
Bevacizumab
3
capmatinib
2
Radiotherapy, Conformal
2
Platinum
2
Paclitaxel
2
Ipilimumab
2
Immunoglobulin G
2
Disulfides
2
Cisplatin
2
CTLA-4 Antigen
2
1,2-diaminocyclohexaneplatinum II citrate
2
veliparib
1
pembrolizumab
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
osimertinib
1
methoxyamine
1
lazertinib
1
fludarabine phosphate
1
durvalumab
1
defactinib
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
2,2'-dithiodiethanesulfonic acid
×
90 days
×
Clear all
NCT05456256
2026-05-04
HARMONIC
Lantern Pharma Inc.
Phase 2
Recruiting
90 enrolled